Maa

JW MARRIOTT MAKES ITS DEBUT IN THE LUXURY SAFARI SEGMENT WITH THE OPENING OF JW MARRIOTT MASAI MARA LODGE

Retrieved on: 
星期一, 四月 3, 2023
Heart, Lion, Small business, Travel, Rejuvenation, Drinking water, Big, Maa, Woman, Recycling, Element, Elephant, Maasai Mara, Mindfulness, JW, Photography, Animal, Water, JW Marriott Indianapolis, Wilderness, Mara, Environment, Book, Well, Hotel, Tourism, JW Marriott Hotels

BETHESDA, Md., April 3, 2023 /PRNewswire/ -- JW Marriott, part of Marriott Bonvoy's global portfolio of 30 extraordinary hotel brands, today announced the opening of JW Marriott Masai Mara Lodge, marking the company's highly anticipated debut in the luxury safari segment.

Key Points: 
  • BETHESDA, Md., April 3, 2023 /PRNewswire/ -- JW Marriott , part of Marriott Bonvoy's global portfolio of 30 extraordinary hotel brands, today announced the opening of JW Marriott Masai Mara Lodge, marking the company's highly anticipated debut in the luxury safari segment.
  • "Fostering meaningful connections and nourishing the soul is at the heart of the JW Marriott brand, so entering the luxury safari segment is a natural next step," said Bruce Rohr, Global Brand Leader, JW Marriott.
  • JW Marriott Masai Mara Lodge is a 30-minute drive from Keekorok Airstrip and a 25-minute drive from Sekenani Main Gate.
  • Bookings for JW Marriott Masai Mara Lodge are now open with prices from $1450 per person, per night (all-inclusive board basis).

Legible Releases First Ever “Living Book” of an Indigenous Story

Retrieved on: 
星期二, 六月 28, 2022
Education, Technology, Other Consumer, Publishing, Online, Entertainment, Communications, Books, Other Technology, Consumer, Other Education, Publishing, EPUB, Living Books, Life, READ, FSE, Book, Company, CSE, Face, Penmanship, Person, Human extinction, Organization, Maa, Language, Nature, Multimedia, Hunting, Sinixt

Were thrilled to see Not Extinct published as a Living Book on the Legible platform as it allows readers to easily engage with the multimedia elements that are integral to this unique project, says KL Kivi of Maa Press.

Key Points: 
  • Were thrilled to see Not Extinct published as a Living Book on the Legible platform as it allows readers to easily engage with the multimedia elements that are integral to this unique project, says KL Kivi of Maa Press.
  • Working with a company like Legible that is championing ground-breaking technology is empowering.
  • Legible Inc. is a book entertainment and media company with a mission: millions of books for billions of readers, globally.
  • Legible Publishing creates multimedia ebooks, branded as Living Books, that empower authors and publishers to deliver dynamic and unique content.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
星期四, 八月 5, 2021
Company, GlaxoSmithKline, Emergency Use Authorization, Royal commission, Committee, Biologics license application, European Commission, Union, United Arab Emirates, Food, Intention, IND, Medicine, Lineage B.1.1.7, European Medicines Agency, GSK, Patient, Maa, COVID-19, CHMP, Severe acute respiratory syndrome coronavirus 2, EMA, BLA, SAN, Joint, Food and Drug Administration, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Biotechnology, BioRxiv, Hospital, Safety, EUA, Death, Ageing, Nivolumab, GLOBE, Pharmaceutical industry, Vaccine

SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
  • The rolling review process is expected to be complete in the second half of 2021.
  • Together with GSK, the Company plans to submit a Biologics License Application (BLA) to the FDA in the second half of 2021.
  • The trial was initiated in June and data are now expected in the second half of 2021.

Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
星期四, 八月 5, 2021
Biotechnology, Pharmaceutical, Health, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Union, Management, EGFR, Kidney failure, Burn, Lupus nephritis, Lupus, Annual report, U.S.–Canada Team Tournament (go), European Medicines Agency, Analysis, EMA, Food and Drug Administration, Proteinuria, Security (finance), Group, EDGAR, Lonza, European Union, Kidney, Person, Diagnosis, Business development, EDT, Growth, Autoimmune disease, SG, Nasdaq, Achievement, Company, Nature, Research, Investment, Webcast, COVID-19, Canadian Securities Administrators, Mission statement, Conversation, Maa, Patient, Adult, Glomerular filtration rate, R, Corporation, Disease, Pharmaceutical industry, Lithium, Cryptocurrency, Animal, Online shopping, Risk management, Lupus Nephritis, Aurinia, LUPUS NEPHRITIS, AURINIA

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today issued its financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today issued its financial results for the second quarter ended June 30, 2021.
  • Aurinia anticipates reporting top-line results from the ongoing AURORA-2 two-year continuation study of voclosporin for the treatment of LN by the end of 2021.
  • Financial Liquidity at June 30, 2021
    As of June 30, 2021, Aurinia had cash and cash equivalents and investments of $323.7 million compared to $422.7 million at December 31, 2020.
  • Aurinia will host a conference call and webcast to discuss the quarter ended June 30, 2021 financial results today, Thursday, August 5, 2021 at 4:30 p.m. EDT.

Cryoport Reports Record Second Quarter 2021 Revenue

Retrieved on: 
星期四, 八月 5, 2021
Company, Investment, U.S. Securities and Exchange Commission, Investor relations, Acquisition, Reproductive medicine, Technology, Adoption, Biologics license application, The Blackstone Group, Regenerative medicine, Fertility clinic, Maas, Maa, Blas, Medicine, BLA, SEC filing, Marketing, SEC, Europe, the Middle East and Africa, APAC, Animal Health, Security (finance), EDT, Animal, Pharmaceutical industry, Lithium, Public relations

Reproductive Medicine revenue increased by $1.7 million, or 283%, to $2.3 million for the second quarter of 2021 compared to $0.6 million for the second quarter of 2020.

Key Points: 
  • Reproductive Medicine revenue increased by $1.7 million, or 283%, to $2.3 million for the second quarter of 2021 compared to $0.6 million for the second quarter of 2020.
  • Total revenue for the second quarter of 2021 increased to $56.2 million compared to $9.4 million for the second quarter of 2020, a year-over-year gain of 498% or 55% organically.
  • Revenue from commercial therapies increased to $3.2 million, a gain of 26% or $0.7 million for the second quarter of 2021
    Animal Health revenue increased to $8.4 million, a gain of 3,726% or $8.2 million for the second quarter of 2021 compared to $0.2 million for the second quarter of 2020, and increased 28% organically
    Reproductive Medicine revenue increased to $2.3 million, a gain of 283% or $1.7 million for the second quarter of 2021 compared to $0.6 million for the second quarter of 2020 and increased 125% organically.
  • Adjusted EBITDA for the second quarter of 2021 was $5.9 million compared to an Adjusted EBITDA loss of $2.5 million for the second quarter of 2020, an increase of $8.5 million over the prior year second quarter.

MIM Software Inc. Receives CE Mark Approval for MAA SPECT/CT Dosimetry

Retrieved on: 
星期四, 八月 5, 2021
MD, European Union, Software, Health, Liver, MIM, Union, Nuclear medicine, Partnership, Engineering, Radiation therapy, Maa, Patient, Microparticle, U.S. News & World Report Best Hospitals Rankings, CE marking, Cancer, PMA, News, Federal Food, Drug, and Cosmetic Act, Yttrium-90, Liver cancer, U.S. News & World Report, Food and Drug Administration, Oh, Regulation of tobacco by the U.S. Food and Drug Administration, Hospital, Engineered Software Inc., Interventional radiology, Floxuridine, Cardiac imaging, Single-photon emission computed tomography, Food, Physician, Medical imaging, Pharmaceutical industry, Management

CLEVELAND, Aug. 5, 2021 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for MAA voxel-based SPECT/CT dosimetry through its MIM SurePlan LiverY90 product.

Key Points: 
  • CLEVELAND, Aug. 5, 2021 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for MAA voxel-based SPECT/CT dosimetry through its MIM SurePlan LiverY90 product.
  • The software allows physicians to quickly calculate the dose delivered by the microspheres to improve treatment decisions and patient care.
  • "With this new dosimetry capability, interventional radiologists can efficiently conduct pre-treatment activity planning using formulas traditionally provided by microsphere manufacturers, as well as take advantage of MAA voxel-based dosimetry simulation," said Aaron Nelson, MD, Chief Medical Officer of MIM Software.
  • MIM Software is used in 16 of the top 20 hospitals listed in the U.S. News & World Report Hospital Rankings & Ratings.

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1

Retrieved on: 
星期四, 八月 5, 2021
Biotechnology, Pharmaceutical, Health, Iron-deficiency anemia, Growth, United States dollar, Manuscript, ANCA, Board, Annual, Marketing, Scd, Income, Hospital, Kidney, Blood, Earnings before interest, taxes, depreciation and amortization, Erythropoiesis-stimulating agent, Review, European Medicines Agency, EMA, Cer, Food and Drug Administration, The New England Journal of Medicine, Sickle cell disease, Therapy, Group, CKD, Anemia, Population, Iron, Mortality, Advisory Committee, European Heart Journal, Depreciation, Dialysis, Raasi, Vifor Pharma, File, Quality of life, Leadership, Hyperkalemia, Awareness, European Space Agency, Pharma, Heart failure, Prescription Drug User Fee Act, Adoption, Annual general meeting, Maa, Executive Committee, Patient, COVID-19, PBM, CHF, NDA, Director, Overalls, Heart, Pharmaceutical industry, Medical device, Aquaculture

Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.

Key Points: 
  • Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.
  • Ferinject / Injectafer net sales increased 22.4% (up 22.8% at CER) to CHF 320.5 million in H1 2021 from CHF 261.9 million a year earlier.
  • As a result, Vifor Pharma posted net sales of CHF 73.7 million, up 1.4% or 8.5% at CER.
  • Abbas Hussain was appointed Chief Executive Officer of Vifor Pharma, succeeding Stefan Schulze, who has decided to step down for personal reasons.

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Retrieved on: 
星期二, 八月 3, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Pregnanes, Sterols, Spacecraft, Ganaxolone, Spaceflight, Seizure, Maa, Orion, Ganaxolone, Marinus Pharmaceuticals, Orion Corporation, GANAXOLONE, MARINUS PHARMACEUTICALS, ORION CORPORATION

This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.

Key Points: 
  • This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.
  • Satu Ahomki, Senior Vice President, Commercial Operations of Orion Corporation said, We are pleased to be the partner of choice for Marinus in Europe.
  • What we have seen so far with ganaxolone is encouraging and signifies an ongoing commitment to the rare epilepsy communities.
  • Marinus expects to file a European marketing authorization application (MAA) for ganaxolone for the treatment of seizures associated with CDD by the end of Q3 2021.

Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

Retrieved on: 
星期二, 一月 26, 2021
FDA, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Anatomy, Branches of biology, Abdomen, Digestive system, Endocrine system, Gastrointestinal tract, Marketing authorisation, Maa, Marketing Authorisation Application, Liver

We look forward to working with the Agency as they review the application over the course of the coming months.

Key Points: 
  • We look forward to working with the Agency as they review the application over the course of the coming months.
  • Vertex plans to submit a Marketing Authorization Application (MAA) variation for the triple combination in the European Union in the first half of 2021 for children ages 6 through 11.
  • Global regulatory filings in additional markets, including Canada and Australia, are planned in the coming months for this age group.
  • CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract.

MAA to Present at Nareit's REITworld: 2020 Annual Conference

Retrieved on: 
星期一, 十一月 16, 2020
Maa, Real estate investment trust, New York Stock Exchange, Germantown, Maryland, New York City

GERMANTOWN, Tenn., Nov. 16, 2020 /PRNewswire/ --Mid-America Apartment Communities, Inc. (NYSE: MAA) ("MAA" or the "Company"), today announced that its management team will make a presentation at Nareit's virtual REITworld: 2020 Annual Conference on Tuesday, November 17, 2020 from 8:45 a.m.

Key Points: 
  • GERMANTOWN, Tenn., Nov. 16, 2020 /PRNewswire/ --Mid-America Apartment Communities, Inc. (NYSE: MAA) ("MAA" or the "Company"), today announced that its management team will make a presentation at Nareit's virtual REITworld: 2020 Annual Conference on Tuesday, November 17, 2020 from 8:45 a.m.
  • The Company's presentation will be available to registered REITworld participants live and on demand on the REITworld website for the duration of the conference.
  • MAA is a self-administered real estate investment trust ("REIT") and member of the S&P 500.
  • MAA owns and manages apartment communities throughout the Southeast, Southwest and Mid-Atlantic regions of the U.S. and is focused on delivering strong, full-cycle investment performance for shareholders.